Neurokinin1 antagonists potentiate antidepressant properties of serotonin reuptake inhibitors, yet blunt their anxiogenic actions: A neurochemical, electrophysiological, and behavioral characterization

Neuropsychopharmacology

Volumn 34, Issue 4, 2009, Pages 1039-1056

  Gobert, Alain ^a   Brocco, Mauricette ^a   Dekeyne, Anne ^a   Di Cara, Benjamin ^a   Bouchez, Gaëlle ^a   Lejeune, Françoise ^a   Gannon, Robert L ^b   Millan, Mark J ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^b VALDOSTA STATE UNIVERSITY   (United States)

Author keywords

Dialysis; Fluoxetine; Neurokinin receptor; SSRI; Substance P

Indexed keywords

1 (1,4 BENZODIOXAN 5 YL) 4 (2 INDANYL)PIPERAZINE; 2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; BUSPIRONE; CITALOPRAM; DOPAMINE; FLUOXETINE; GR 226206; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROKININ 1 RECEPTOR ANTAGONIST; NORADRENALIN; PINDOLOL; SEROTONIN; UNCLASSIFIED DRUG; VOFOPITANT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ISOINDOLE DERIVATIVE; NEUROKININ 1 RECEPTOR; PIPERIDINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; TETRAZOLE DERIVATIVE;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BRAIN ELECTROPHYSIOLOGY; CIRCADIAN RHYTHM; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG POTENTIATION; FORCED SWIMMING TEST; FRONTAL CORTEX; HIPPOCAMPUS; LOCOMOTION; MALE; MOUSE; NERVE CONDUCTION; NEUROCHEMISTRY; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAPHE NUCLEUS; RAT; SEROTONINERGIC NERVE CELL; SOCIAL INTERACTION; STEREOSPECIFICITY; TRANQUILIZING ACTIVITY; ANIMAL; ANIMAL BEHAVIOR; BRAIN; DRUG ANTAGONISM; GERBIL; HAMSTER; METABOLISM; NERVE CELL; PHYSIOLOGY; SYRIAN HAMSTER; WISTAR RAT;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BRAIN; CITALOPRAM; CRICETINAE; DOPAMINE; DRUG SYNERGISM; FLUOXETINE; GERBILLINAE; ISOINDOLES; MALE; MESOCRICETUS; MICE; NEURONS; NOREPINEPHRINE; PIPERIDINES; RATS; RATS, WISTAR; RECEPTORS, NEUROKININ-1; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; TETRAZOLES;

EID: 59949091430     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2008.176     Document Type: Article

References (97)

1. Adell A, Artigas F (2004). The somatodendritic release of dopamine in the ventral tegmental area and its regulation by afferent transmitter systems. Neurosci Biobehav Rev 28: 415-431.
2. Alex KD, Pehek EA (2007). Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 113: 296-320.
3. Artigas F, Celada P, Laruelle M, Adell A (2001). How does pindolol improve antidepressant action? TIPS 22: 224-228.
4. Bassi GS, Nobre MJ, Carvalho MC, Brandão ML (2007). Substance P injected into the dorsal periaqueductal gray causes anxiogenic effects similar to the long-term isolation as assessed by ultrasound vocalizations measurements. Behav Brain Res 182: 301-307.
5. 1 receptor-mediated activation of the locus coeruleus revealed by SR 142801. Synapse 43: 62-69.
6. Blier P, Gobbi G, Haddjeri N, Santarelli L, Mathew G, Hen R (2004). Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response. J Psychiatry Neurosci 29: 208-218.
7. 1 receptor antagonist, vestipitant: a comparison to other agents. Eur Neuropsychopharmacol 18: 729-750.
8. 2 receptors. Behav Pharmacol 17: 559-572.
9. Brocco M, Dekeyne A, Veiga S, Girardon S, Millan MJ (2002). Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake a pharmacological characterization of diverse classes of antidepressant agents. Pharmacol Biochem Behav 71: 667-680.
10. 2C receptor antagonist. Biol Psychiatry 62: 1111-1118.
11. 2C receptors within the basolateral amygdala induce acute fear-like responses in an open-field environment. Brain Res 993: 1-9.
12. Celada P, Puig MV, Casanovas JM, Guillazo G, Artigas F (2001). Control of dorsal raphe serotonergic neurons by the medial prefrontal cortex: involvement of serotonin-1A, GABA(A), and glutamate receptors. J Neurosci 21: 9917-9929.
13. 1 receptor antagonist in the mouse forced swimming test. Behav Brain Res 172: 256-263.
14. Commons KG, Valentino RJ (2002). Cellular basis for the effects of substance P in the periaqueductal gray and dorsal raphe nucleus. J Comp Neurol 447: 82-97.
15. Conley RK, Cumberbatch MJ, Mason GS, Williamson DJ, Harrison T, Locker K et al (2002). Substance P (neurokinin 1) receptor antagonists enhance dorsal raphe neuronal activity. J Neurosci 22: 7730-7736.
16. 2C antagonists: mechanistic studies. Neuropsychopharmacology 31: 1550-1557.
17. 1 receptor antagonists under investigation for the treatment of affective disorders. Expert Opin Investig Drugs 15: 479-486.
18. Dableh LJ, Yashpal K, Rochford J, Henry JL (2005). Antidepressant-like effects of neurokinin receptor antagonists in the forced swim test in the rat. Eur J Pharmacol 507: 99-105.
19. De Vry J, Benz U, Schreiber R, Traber J (1993). Shock-induced ultrasonic vocalization in young adult rats: a model for testing putative anti-anxiety drugs. Eur J Pharmacol 249: 331-339.
20. 2C receptors. Neuropharmacology 39: 114-1117.
21. Duncan WC (1996). Circadian rhythms and the pharmacology of affective illness. Pharmacol Ther 71: 253-312.
22. Ebner K, Rupniak NM, Saria A, Singewald N (2004). Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proc Natl Acad Sci USA 101: 4280-4285.
23. Ebner K, Singewald GM (2007). Stress-induced release of substance P in the locus coeruleus modulates cortical noradrenaline release. Naunyn Schmiedebergs Arch Pharmacol 376: 73-82.
24. 1A transmission. Neuropsychopharmacology 33: 1929-1941.
25. 1 receptors. Biochem Pharmacol 73: 259-269.
26. 1 receptor antagonist in the social interaction test. Pharmacol Biochem Behav 58: 747-752.
27. 1) receptor knock-out mice mimic antidepressant-induced desensitization. Neuroscience 15: 8188-8197.
28. Furmark T, Appel L, Michelga° rd A, Wahlstedt K, Ahs F, Zancan S et al (2005). Cerebral flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram or placebo. Biol Psychiatry 58: 132-142.
29. 1) receptor antagonist, GR 205171, stereospecifically inhibits light-induced phase shifts of hamster circadian activity rhythms. Eur J Pharmacol 527: 86-93.
30. Gannon RL, Millan MJ (2007). Evaluation of serotonin, noradrenaline and dopamine reuptake inhibitors on light-induced phase advances in hamster circadian activity rhythms. Psychopharmacology 195: 325-332.
31. 1receptor, and potent broad-spectrum anti-emetic activity. Regul Pept 65: 45-53.
32. Garret C, Carruette A, Fardin V, Moussoui S, Peyronel JF, Blanchard JC et al (1991). Pharmacological properties of a potent and selective nonpeptide substance P antagonist. Proc Natl Acad Sci USA 88: 10208-10212.
33. Gerald CPG, Antonijevic IA, Branchek TA (2006). Novel mechanisms to treat depression and anxiety. Will neuropeptide antagonists succeed? Drug Discov Today Ther Strateg 4: 467-473.
34. Gobbi G, Cassano T, Radja F, Morgese MG, Cuomo V, Santarelli L et al (2007). Neurokinin 1 receptor antagonism requires norepinephrine to increase serotonin function. Eur Neuropsychopharmacol 17: 328-338.
35. 1A receptor agonists and antagonists: A comparison to adrenergic and dopaminergic neurones in individual rats. J Pharmacol Exp Ther 273: 1032-1046.
36. 2-adrenergic receptors underlie its actions. Neuroscience 93: 1251-1262.
37. 1B receptors with WAY100 635 and GR127 935. J Neurochem 68: 1159-1163.
38. 1receptor binding profile in gerbil and human brain. Br J Pharmacol 148: 39-45.
39. 1A autoreceptors in mice. J Neurochem 95: 1713-1723.
40. 1 receptor activation within the dorsal raphe nucleus controls serotonin release in the mouse frontal cortex. Mol Pharmacol 72: 1411-1418.
41. 1) receptors enhances extracellular serotonin when combined with a selective serotonin reuptake inhibitor: an in vivo microdialysis study in mice. J Neurochem 89: 54-63.
42. 1A receptor knockout mice. Neuropsychopharmacology 31: 2162-2172.
43. 1 receptor antagonists on the function of 5-HT and noradrenaline neurons. Neuroreport 11: 1323-1327.
44. 1 receptors enhances serotonin neurotransmission. Biol Psychiatry 50: 191-199.
45. Haddjeri N, Lucas G, Blier P (2000). Role of cholinergic and GABAergic systems in the feedback inhibition of dorsal raphe 5-HT neurons. Neuroreport 11: 3397-3401.
46. 1-/-) and wildtype mice: exploratory behaviour and extracellular noradrenaline concentration in the cerebral cortex of anaesthetised subjects. Neuropharmacology 48: 706-719.
47. Holmes A, Heilig M, Rupniak NMJ, Steckler T, Griebel G (2003). Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci 24: 580-588.
48. 2C receptors stimulates GABA-ergic function in the rat substantia nigra pars reticulata: a combined in vivo electrophysiological and neurochemical study. Neuroscience 144: 1523-1535.
49. Kramer MS, Cutler NR, Keighner J, Shrivastava R, Carman J, Sramek JJ et al (1998). Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281: 1640-1645.
50. 1) receptor antagonist in major depression. Neuropsychopharmacology 29: 385-392.
51. 1) in serotonin neurons of rat and mouse dorsal raphe nucleus. Eur J Neurosci 23: 2947-2958.
52. 3-immunoreactive neurons in serotonergic cell groups in the rat brain. Neurosci Lett 323: 146-150.
53. Legutko R, Gannon RL (2001). Serotonin transporter localization in the hamster suprachiasmatic nucleus. Brain Res 893: 77-83.
54. 1 antagonist, GR205171, stereospecifically enhances mesocortical dopaminergic transmission in the rat: a combined dialysis and electrophysiological study. Brain Res 935: 134-139.
55. 1A receptors. Eur J Neurosci 12: 3265-3275.
56. 1A receptors and their modulation of the activity of serotonergic and dopaminergic neurones in rats. J Pharmacol Exp Ther 280: 1241-1249.
57. Lessard A, Pickel VM (2005). Subcellular distribution and plasticity of neurokinin-1 receptors in the rat substantia nigra and ventral tegmental area. Neuroscience 135: 1309-1323.
58. 1 receptor antagonists on serotonin uptake in human and rat brain synaptosomes. Eur Neuropsychopharmacol 15: 641-646.
59. Liu R, Ding Y, Aghajanian GK (2002). Neurokinins activate local glutamatergic inputs to serotonergic neurons of the dorsal raphe nucleus. Neuropsychopharmacology 27: 329-340.
60. Lucki I, Singh A, Kreiss DS (1994). Antidepressant-like behavioral effects of serotonin receptor agonists. Neurosci Biobehav Rev 18: 85-95.
61. 1 receptors in rats. Neuroreport 13: 1809-1813.
62. 1) receptor antagonist and conventional antidepressant treatment increases burst firing of monoamine neurones in the locus coeruleus. Neuroscience 109: 609-617.
63. 1 receptor system. Biol Psychiatry 61: 1002-1006.
64. Millan MJ (2003). The neurobiology and control anxious states. Prog Neurobiol 70: 83-244.
65. Millan MJ (2004). The role of monoamines in the action of established and 'novel' antidepressant agents: a critical review. Eur J Pharmacol 500: 371-384.
66. Millan MJ (2006). Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 110: 135-370.
67. 1 antagonists, CP154 526 and DMP695: a comparison to other classes of anxiolytic agent. Neuropsychopharmacology 25: 585-600.
68. Millan MJ, Gobert A (1999). (-)-Pindolol increases dialysate concentrations of dopamine and noradrenaline, but not serotonin, in the frontal cortex of freely-moving rats. Neuropharmacology 38: 909-912.
69. 1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties. J Pharmacol Exp Ther 282: 148-161.
70. 1 receptors facilitates the activity of adrenergic pathways projecting to the frontal cortex and dorsal hippocampus in the rat. J Neurochem 76: 1949-1954.
71. Millan MJ, Lejeune F, Gobert A (2000). Reciprocal autoreceptor and heteroceptor control of serotonergic, dopaminergic and adrenergic transmission in frontal cortex: a review, and relevance to the actions of antidepressant agents. J Psychopharmacol 14: 114-138.
72. 1A, dopamine hD2/hD3 and hα2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity. J Pharmacol Exp Ther 282: 132-147.
73. Molewijk HE, Hartog K, van der Poel AM, Mos J, Olivier B (1996). Reduction of guinea pig pup isolation calls by anxiolytic and antidepressant drugs. Psychopharmacology 128: 31-38.
74. Morilak DA, Frazer A (2004). Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. Int J Neuropsychopharmacol 7: 193-218.
75. 1A receptors. Neuropsychopharmacology 18: 395-398.
76. Redrobe JP, Bourin M (1998). Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test. Psychopharmacology 138: 198-206.
77. 1 receptors attenuates stress-induced rise of extracellular noradrenaline and dopamine in the rat and gerbil medial prefrontal. J Neurosci Res 84: 961-968.
78. 1) receptors attenuates neonatal vocalisation in guinea-pigs and mice. Neuropharmacology 39: 1413-1421.
79. 1) receptor in assays for antidepressant and anxiolytic drugs. Behav Pharmacol 12: 497-508.
80. 1) receptor antagonist L-760735 inhibits fear conditioning in gerbils. Neuropharmacology 44: 516-523.
81. 1 antagonists-serotonin reuptake inhibitors as potential antidepressants. Part 2: SAR and activity of benzyloxyphenethyl piperazine derivatives. Bioorg Med Chem Lett 12: 3195-3198.
82. 3 binding sites. Neuroscience 116: 761-773.
83. Salchner P, Singewald N (2006). 5-HT receptor subtypes involved in the anxiogenic-like action and associated Fos response of acute fluoxetine treatment in rats. Psychopharmacology 185: 282-288.
84. Sánchez C (2003). Stress-induced vocalization in adult animals. A valid model of anxiety? Eur J Pharmacol 463: 133-143.
85. Sanchez C, Meier E (1997). Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Psychopharmaocology 129: 197-205.
86. Santarelli L, Gobbi G, Debs PC, Sibille EL, Blier P, Hen R et al (2001). Genetic and pharmacological distribution of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc Natl Acad Sci USA 98: 1912-1917.
87. Sartori SB, Burnet PWJ, Sharp T, Singewald N (2004). Evaluation of the effect of chronic antidepressant treatment on neurokinin-1 receptor expression in the rat brain. Neuropharmacology 46: 1177-1183.
88. Sharp T, Boothman L, Raley J, Quérée P (2007). Important messages in the 'post': recent discoveries in 5-HT neurone feedback control. TiNS 28: 629-636.
89. Sheehan TP, Chambers RA, Russell DS (2004). Regulation of affect by the lateral septum: implications for neuropsychiatry. Brain Res Rev 46: 71-117.
90. Shirayama Y, Mitsushio H, Takashima M, Ichikawa H, Takahashi K (1996). Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat. Brain Res 739: 70-78.
91. Sloviter RS, Ali-Akbarian L, Horvath KD, Menkens KA (2001). Substance P receptor expression by inhibitory interneurons of the rat hippocampus: enhanced detection using improved immunocytochemical methods for the preservation and colocalization of GABA and other neuronal markers. J Comp Neurol 430: 283-305.
92. 3 receptor antagonists: the next generation of antipsychotics? Nat Rev Drug Discov 4: 967-975.
93. 1 receptors GABA release at synapses in rat entorhinal cortex. Neuroscience 115: 575-586.
94. 2 receptors produces antidepressant-like effects associated with reduced corticotrophin-releasing factor function. J Pharmacol Exp Ther 299: 449-458.
95. Szeidemann Z, Jakab RL, Shanabrough M, Leranth C (1995). Extrinsic and intrinsic substance P innervation of the rat lateral septal area calbindin cells. Neuroscience 69: 1205-1221.
96. Valentino RJ, Bey V, Pernar L, Commons KG (2003). Substance P acts through local circuits within the rat dorsal raphe nucleus to alter serotonergic neuronal activity. J Neurosci 23: 7155-7159.
97. 1 receptor antagonists. Neuropsychopharmacology 27: 371-379.